Correction to: Neuropsychopharmacology https://doi.org/10.1038/s41386-022-01421-2, published online 13 September 2022
The technical name of the compound studied in this article was incorrectly referred to as SEP-383856 in the title and the abstract and has now been corrected to SEP-363856. None of the scientific conclusions in this paper are affected by this correction. The original article has been corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Saarinen, M., Mantas, I., Flais, I. et al. Correction To: TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP- 363856. Neuropsychopharmacol. 48, 846 (2023). https://doi.org/10.1038/s41386-022-01504-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41386-022-01504-0
